The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Waning factor VIII levels mean the durability question is still unanswered.
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.